What Researchers Did
Researchers conducted a prospective observational study across multiple tertiary care hospitals to evaluate if adding hyperbaric oxygen therapy (HBOT) to conventional treatment benefits patients with idiopathic sudden sensorineural hearing loss (SNHL).
What They Found
Among 27 patients, 46.6% in the HBOT group (Group A) and 41.6% in the conventional treatment group (Group B) showed recovery. Conversely, 53.3% of Group A and 58.3% of Group B experienced no recovery, and the observed difference in success rates between groups was not statistically significant (p>0.05).
What This Means for Canadian Patients
Canadian patients with idiopathic sudden sensorineural hearing loss may find that adding hyperbaric oxygen therapy (HBOT) to their conventional treatment offers no additional benefit. However, for those unable to receive conventional therapy due to contraindications, HBOT could be considered as an alternative treatment option.
Canadian Relevance
This study has no direct Canadian connection as it was conducted at multicentre tertiary care hospitals outside of Canada.
Study Limitations
A key limitation of this study is its small sample size of 27 cases, which may limit the generalizability and statistical power of the findings.